Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Drug Deliv. 2005 Oct;2(4):401-6.

Lipid-protamine-DNA-mediated antigen delivery.

Author information

1
Center for Pharmacogenetics, School of Pharmacy, University of Pittsburgh, Pittsburgh, USA.

Abstract

The development of novel 'new generation' vaccine systems that is based on proteins, peptides or DNA is of great current interest. However, due to the lower efficiencies of these new generation vaccines, they are seldomly used alone. Rather, their formulations often contain adjuvants, either to enhance the immune responses or to reduce dosing. The present chapter will provide a brief overview of the recent advances in peptide-based cancer vaccine adjuvants, focusing mainly on Liposome-Protamine-DNA (LPD) nanoparticle-mediated antigen delivery.

PMID:
16305443
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Bentham Science Publishers Ltd.
    Loading ...
    Support Center